Trexquant Investment LP Acquires 508,362 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Trexquant Investment LP increased its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 867.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 566,945 shares of the company's stock after buying an additional 508,362 shares during the period. Trexquant Investment LP owned about 0.73% of Kura Oncology worth $4,938,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Rhumbline Advisers increased its holdings in Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock worth $871,000 after acquiring an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares during the last quarter. Teacher Retirement System of Texas raised its stake in Kura Oncology by 19.9% in the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after acquiring an additional 2,285 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Kura Oncology by 0.8% during the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. StockNews.com upgraded Kura Oncology from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. Scotiabank lowered their price target on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a report on Wednesday, January 8th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded down $0.40 during trading hours on Thursday, reaching $5.57. 448,772 shares of the stock traded hands, compared to its average volume of 1,111,538. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $449.89 million, a price-to-earnings ratio of -2.37 and a beta of 0.83. The company has a 50 day moving average price of $7.47 and a 200 day moving average price of $11.06. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. On average, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last three months. Company insiders own 5.50% of the company's stock.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.